AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
OS Therapies Incorporated
XASE · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00Y71N7H6
1.25▲ 0.00 (0.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
1.25
Day's Range
1.23 – 1.29
52-Week Range
1.15 – 2.25
Volume
141.9K
Avg Volume
736.1K
Share Statistics
Shares Outstanding
Employees
5
Exchange
XASE
Listed
2024-08-01
Share count as of December 31, 2026

OS Therapies Incorporated (OSTX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about OS Therapies Incorporated (OSTX)
What is OS Therapies Incorporated's Market Cap?
OS Therapies Incorporated's Market Cap is $46.4M, based on as-reported figures from SEC (XBRL) filings.
What is OS Therapies Incorporated's Net Income (TTM)?
OS Therapies Incorporated's Net Income (TTM) is -$39.4M, based on as-reported figures from SEC (XBRL) filings.
What is OS Therapies Incorporated's EBITDA?
OS Therapies Incorporated's EBITDA is -$37.1M, based on as-reported figures from SEC (XBRL) filings.
What is OS Therapies Incorporated's Diluted EPS (TTM)?
OS Therapies Incorporated's Diluted EPS (TTM) is -1.06, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · OSTXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023
OPERATING EXPENSES
Research and development
General and administrative
Loss from operations
OTHER (EXPENSE) INCOME
Interest income
Interest expense——
Non-operating expenses——
Change in fair value of warrant liability——
TOTAL OTHER (EXPENSE) INCOME
NET LOSS
NET LOSS available to common shareholders
Basic loss per common share outstanding (in Dollars per share)
Diluted loss per common share outstanding (in Dollars per share)